American Journal of Ophthalmology
Volume 149, Issue 2 , Pages 179-181 , 1 February 2010

At the Frontier of Vision Research: The National Eye Institute Celebrates 40 Years

  • Paul A. Sieving

      Affiliations

    • Corresponding Author InformationInquiries to Paul A. Sieving, National Eye Institute, National Institutes of Health, 31 Center Drive, Room 6A03, MSC 2510, Bethesda, MD 20892-2510

,Accepted 15 October 2009.

References 

  1. Lichter PR. Serving the public's interest—the National Eye Institute celebrates 25 years. Ophthalmology. 1993;100:295–296
  2. A brief history of the National Eye Institute. In: Government Publications Review. 1955;p. 12
  3. NIH Legislative Highlights (NEI Files). 1968;
  4. Fine SL. Clinical trials and the practice of ophthalmology. Arch Ophthalmol. 1984;102:1282–1285
  5. Kupfer C. The challenge of transferring research results into patient care. Ophthalmology. 1989;96:737–738
  6. Preliminary report on effects of photocoagulation therapy (The Diabetic Retinopathy Study Research Group). Am J Ophthalmol. 1976;81:383–396
  7. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy (Four-year results of a randomized trial: Diabetic Retinopathy Vitrectomy Study Report 5). Arch Ophthalmol. 1990;108:958–964
  8. Indications for photocoagulation treatment of diabetic retinopathy (Diabetic Retinopathy Study Report Number 14). Investigative Ophthalmology and Visual Science. 1994;27:239–253
  9. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943–1953
  10. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713discussion 829–830
  11. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol. 2001;119:1439–1452
  12. Chepelinsky AB, King CR, Zelenka PS, Piatigorsky J. Lens-specific expression of the chloramphenicol acetyltransferase gene promoted by 5′ flanking sequences of the murine alpha A-crystallin gene in explanted chicken lens epithelia. Proc Natl Acad Sci U S A. 1985;82:2334–2238
  13. Mahon KA, Chepelinsky AB, Khillan JS, Overbeek PA, Piatigorsky J, Westphal H. Oncogenesis of the lens in transgenic mice. Science. 1987;235:1622–1628
  14. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 1986;323:643–646
  15. Schertler GF, Villa C, Henderson R. Projection structure of rhodopsin. Nature. 1993;362:770–772
  16. Preston GM, Agre P. Isolation of the cDNA for erythrocyte integral membrane protein of 28 kilodaltons: member of an ancient channel family. Proc Natl Acad Sci U S A. 1991;88:11110–11114
  17. Agre P, Sasaki S, Chrispeels MJ. Aquaporins: a family of water channel proteins. Am J Physiol. 1993;265:F461
  18. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308:419–421
  19. Edwards AO, Ritter R, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005;308:421–424
  20. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther. 2009;20:999–1004
  21. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A. 2005;102:7227–7232
  22. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385–389
  23. Zareparsi S, Branham KEH, Li M, et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet. 2005;77:149–153

PII: S0002-9394(09)00798-3

doi: 10.1016/j.ajo.2009.10.016

American Journal of Ophthalmology
Volume 149, Issue 2 , Pages 179-181 , 1 February 2010

Article Tools